- Email: [email protected]
Method and apparatus for preparing fibrinogen adhesive from whole blood
Pergamon
Transfus. Sci. Vo1.15, No.1, pp. i-iv, 1994
ElsevierScience Ltd. Printedin Great Britain 0955-3886194 $7.00 + 0.00
0955-3886(94)EOOll-7
NEW PATENTS This section contains abstracts and, where appropriate, illustrations of recently issued United
States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the PATSEARCH@ online database in accordance with interest profiles developed by the Editors.
Further information about online patent searching can be obtained from Research on Demand Inc., 2421 Fourth Street, Ste. C., Berkeley, CA 94710, U.S.A. (Tel. 510-841 1145; Fax 510-841 6311).
5225181
5227302
RADIOLABELED ANTIPLATELET MONOCLONAL ANTIBODY FOR IMAGING IN-VIVO THROMBI
DNA ENCODING PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR (PD-ECGF)
Suresh C Srivastava, Barry S Coller, George E Meinken assigned to The Research Foundation of State University of New York
Carl-Henrik Heldin, Kohei Miyazono, Christer Wemstedt, Ulf G T Hellman, Fumimaro Takaku, Fuyuki Ishikawa, Uppsala, Sweden assigned to Ludwig Institute for Cancer Research
There is provided a radiolabeled monoclonal antibody of the class IgGl which reacts readily with both normal human and dog blood platelets while failing to react with thrombasthenic human platelets. This antibody has the property of completely blocking interaction of fibrinogen with platelets induced by ADP, and the ability to detect fresh thrombi in vivo.
5226877 METHOD AND APPARATUS FOR PREPARING FIBRINOGEN ADHESIVE FROM WHOLE BLOOD Gordon
Epstein
A process and apparatus for one-step preparation of fibrinogen adhesive by polyethylene glycol-mediated precipitation from plasma are disclosed. The methods and apparatus of the invention permit preparation of autologous fibrinogen adhesive composition from the patient during surgery, and can be applied generally to provide such compositions. Also disclosed are an apparatus and method for application of sealant comprising this fibrinogen adhesive composition.
Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family.PD-ECGF appears to be the only endothelialcell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e., the ability to stimulate the formation of new blood vessels and chemotactic activity, in vitro. The present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past, the primary structure of PD-ECGF, antibodies against PD-ECGF, clones of its cDNA, and variants thereof. The invention also provides a therapeutic preparation of PD-ECGF.
5227469 PLATELET AGGREGATION INHIBITORS FROM THE LEECH Robert A Lazarus, Genentech Inc A
composition
Jana Seymour
of
matter
assigned
derived
to
from
Transfus. Sci. Vo1.15, No.1, pp. i-iv, 1994
ElsevierScience Ltd. Printedin Great Britain 0955-3886194 $7.00 + 0.00
0955-3886(94)EOOll-7
NEW PATENTS This section contains abstracts and, where appropriate, illustrations of recently issued United
States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the PATSEARCH@ online database in accordance with interest profiles developed by the Editors.
Further information about online patent searching can be obtained from Research on Demand Inc., 2421 Fourth Street, Ste. C., Berkeley, CA 94710, U.S.A. (Tel. 510-841 1145; Fax 510-841 6311).
5225181
5227302
RADIOLABELED ANTIPLATELET MONOCLONAL ANTIBODY FOR IMAGING IN-VIVO THROMBI
DNA ENCODING PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR (PD-ECGF)
Suresh C Srivastava, Barry S Coller, George E Meinken assigned to The Research Foundation of State University of New York
Carl-Henrik Heldin, Kohei Miyazono, Christer Wemstedt, Ulf G T Hellman, Fumimaro Takaku, Fuyuki Ishikawa, Uppsala, Sweden assigned to Ludwig Institute for Cancer Research
There is provided a radiolabeled monoclonal antibody of the class IgGl which reacts readily with both normal human and dog blood platelets while failing to react with thrombasthenic human platelets. This antibody has the property of completely blocking interaction of fibrinogen with platelets induced by ADP, and the ability to detect fresh thrombi in vivo.
5226877 METHOD AND APPARATUS FOR PREPARING FIBRINOGEN ADHESIVE FROM WHOLE BLOOD Gordon
Epstein
A process and apparatus for one-step preparation of fibrinogen adhesive by polyethylene glycol-mediated precipitation from plasma are disclosed. The methods and apparatus of the invention permit preparation of autologous fibrinogen adhesive composition from the patient during surgery, and can be applied generally to provide such compositions. Also disclosed are an apparatus and method for application of sealant comprising this fibrinogen adhesive composition.
Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45 kDa endothelial cell mitogen that has been purified to homogeneity from human platelets. It does not bind to heparin and does not stimulate the proliferation of fibroblasts, in contrast to other endothelial mitogens of the fibroblast growth factor (FGF) family.PD-ECGF appears to be the only endothelialcell growth factor in human platelets and recent data indicate that it has angiogenic activity in vitro, i.e., the ability to stimulate the formation of new blood vessels and chemotactic activity, in vitro. The present invention provides a homogeneous PD-ECGF in substantially greater yields than available in the past, the primary structure of PD-ECGF, antibodies against PD-ECGF, clones of its cDNA, and variants thereof. The invention also provides a therapeutic preparation of PD-ECGF.
5227469 PLATELET AGGREGATION INHIBITORS FROM THE LEECH Robert A Lazarus, Genentech Inc A
composition
Jana Seymour
of
matter
assigned
derived
to
from